AbbVie Inc (ABBV) - Total Liabilities
Based on the latest financial reports, AbbVie Inc (ABBV) has total liabilities worth $137.19 Billion USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of AbbVie Inc to assess how effectively this company generates cash.
AbbVie Inc - Total Liabilities Trend (2010–2025)
This chart illustrates how AbbVie Inc's total liabilities have evolved over time, based on quarterly financial data. Check ABBV asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
AbbVie Inc Competitors by Total Liabilities
The table below lists competitors of AbbVie Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SK hynix Inc
F:HY9H
|
Germany | €48.43 Trillion |
|
Netflix Inc
NASDAQ:NFLX
|
USA | $28.98 Billion |
|
Advanced Micro Devices Inc
NASDAQ:AMD
|
USA | $13.93 Billion |
|
Chevron Corp
NYSE:CVX
|
USA | $131.84 Billion |
|
Berkshire Hathaway Inc
NYSE:BRK-A
|
USA | $502.47 Billion |
|
Caterpillar Inc
NYSE:CAT
|
USA | $77.27 Billion |
|
Bank of America Corp
NYSE:BAC
|
USA | $3.11 Trillion |
|
Procter & Gamble Company
NYSE:PG
|
USA | $73.97 Billion |
Liability Composition Analysis (2010–2025)
This chart breaks down AbbVie Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ABBV company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.67 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -41.95 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.02 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how AbbVie Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for AbbVie Inc (2010–2025)
The table below shows the annual total liabilities of AbbVie Inc from 2010 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $137.19 Billion | +4.09% |
| 2024-12-31 | $131.80 Billion | +6.02% |
| 2023-12-31 | $124.31 Billion | +2.30% |
| 2022-12-31 | $121.52 Billion | -7.30% |
| 2021-12-31 | $131.09 Billion | -4.64% |
| 2020-12-31 | $137.47 Billion | +41.30% |
| 2019-12-31 | $97.29 Billion | +43.50% |
| 2018-12-31 | $67.80 Billion | +3.21% |
| 2017-12-31 | $65.69 Billion | +6.88% |
| 2016-12-31 | $61.46 Billion | +25.17% |
| 2015-12-31 | $49.10 Billion | +90.54% |
| 2014-12-31 | $25.77 Billion | +4.31% |
| 2013-12-31 | $24.71 Billion | +4.49% |
| 2012-12-31 | $23.64 Billion | +211.57% |
| 2011-12-31 | $7.59 Billion | +39.72% |
| 2010-12-31 | $5.43 Billion | -- |
About AbbVie Inc
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various c… Read more